hit counter
Cambrex Corporation (CBM) Stock News Sentiment & Price - Sentifly
CBM - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cambrex Corporation (CBM)

USA
Biotechnology
NYSE
CBM Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CBM Latest news
PRNewsWire
Neutral
Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh
2020-10-12 04:00

EAST RUTHERFORD, N.J., Oct. 12, 2020 /PRNewswire/ -- Cambrex, announced today the completion of an expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland. This major expansion project has seen the facility's total footprint doubled to...

GlobeNewsWire
Neutral
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility
2020-04-07 08:45

EAST RUTHERFORD, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site. Biopharmaceutical analysis services were initially launched at Durham in 2018 and have since been expanded through the purchase and implementation of various method development, validation, release and stability or endotoxin testing functions.

GlobeNewsWire
Neutral
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility
2020-04-07 08:45

EAST RUTHERFORD, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site. Biopharmaceutical analysis services were initially launched at Durham in 2018 and have since been expanded through the purchase and implementation of various method development, validation, release and stability or endotoxin testing functions.

GlobeNewsWire
Neutral
Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit
2020-03-31 08:00

EAST RUTHERFORD, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT). In his new role, he has responsibility for operations at the Agawam, Massachusetts; Durham, North Carolina; Edinburgh, UK; High Point, North Carolina and Longmont, Colorado facilities.

GlobeNewsWire
Neutral
Cambrex Announces Completion of Acquisition by the Permira Funds
2019-12-04 09:27

EAST RUTHERFORD, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affiliate of the Permira funds.

Zacks Investment Research
Neutral
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
2019-11-18 09:30

ALXN vs. CBM: Which Stock Is the Better Value Option?

Zacks Investment Research
Neutral
ALXN or CBM: Which Is the Better Value Stock Right Now?
2019-10-31 09:30

ALXN vs. CBM: Which Stock Is the Better Value Option?

GlobeNewsWire
Neutral
Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
2019-09-23 06:40

EAST RUTHERFORD, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), which provides for the Company to be acquired by an affiliate of the Permira funds in an all-cash transaction for $60.00 per share. At the direction of the ad hoc committee of the Company’s Board of Directors, the Company’s financial advisor engaged in solicitation of 77 potential bidders, which resulted in eight potential bidders each entering into a confidentiality agreement with the Company. Each of the eight parties that entered into a confidentiality agreement with the Company was provided access to nonpublic information regarding the Company and the opportunity to have access to Company management. As of the expiration of the go-shop period, the Company had

Zacks Investment Research
Positive
CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
2019-06-25 09:30

CBM vs. ALKS: Which Stock Is the Better Value Option?

Zacks Investment Research
Positive
CBM vs. TECH: Which Stock Is the Better Value Option?
2019-05-21 09:30

CBM vs. TECH: Which Stock Is the Better Value Option?

Loading more news...